Albert Bourla, CEO of Pfizer, speaking on Squawk on the Street at the World Economic Forum in Davos, Switzerland on Jan. 20, 2026.Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December.The pharmaceutical giant is looking to longer-term investments in its pipeline, including its $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product ...

每经AI快讯，2月3日消息，辉瑞制药第四季度营收175.6亿美元；第四季度调整后每股收益0.66美元。 公司仍然预测2026年营收595亿美元至625亿美元。 ...

辉瑞：目前的财务指引未预计2026年有任何股票回购计划。 来源：滚动播报 ...

辉瑞股价盘前下跌2.1%。 来源：滚动播报 ...

辉瑞制药公司仍然预测2026年调整后每股收益2.80美元至3.00美元。 来源：滚动播报 ...

辉瑞制药公司第四季度调整后每股收益0.66美元。 来源：滚动播报 ...

来源：滚动播报 辉瑞业绩指引纳入关税带来的预期影响，2026年指引反映了最惠国药品定价和特朗普处方药政策预计带 来的不利影响。 ...

Core Insights - Pfizer reported fourth-quarter profit exceeding Wall Street estimates, driven by sustained demand for older drugs like blood thinner Eliquis, which helped mitigate declining sales from COVID-related products [1] Financial Performance - The company’s fourth-quarter profit was above expectations, indicating strong performance in its traditional drug portfolio despite challenges in the COVID product segment [1]

Core Insights - Pfizer's experimental obesity drug demonstrated a weight loss of up to 12.3% in patients without diabetes during a mid-stage trial [1] Company Summary - The obesity drug was acquired through the Metsera deal, indicating Pfizer's strategic expansion into the obesity treatment market [1]

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 GuidanceFeb 3, 2026 6:45 AM Eastern Standard Time# Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 GuidanceShare---- Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026- Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline- Focused Execution Drives Strong Full-Year 2025 EPS PerformanceNEW YORK--([BUSINESS WIRE])--Pfizer Inc. (NYSE: PFE) reported financial results fo ...